11-hydroxy-N-(n-propyl)noraporphine
RN given refers to parent cpd without isomeric designation; (R)-isomer is a dopamine agonist; (S)-isomer is a dopamine antagonist
Also Known As:
11-OH-NPa; 11-hydroxy-N-(n-propyl)noraporphine hydrochloride, (R)-isomer; 11-hydroxy-N-(n-propyl)noraporphine hydrochloride, (S)-isomer; 11-hydroxy-N-(n-propyl)noraporphine hydroiodide; 11-hydroxy-N-(n-propyl)noraporphine hydroiodide, (+-)-isomer; 11-hydroxy-N-(n-propyl)noraporphine, (+-)-isomer; 11-hydroxy-N-(n-propyl)noraporphine, (R)-isomer; 11-hydroxy-N-(n-propyl)noraporphine, (S)-isomer; 11-hydroxy-N-n-propylnorapomorphine; 11-hydroxy-N-n-propylnoraporphine; 5,6,6a,7-tetrahydro-6-propyl-4H-dibenzo(de,g)quinolin-11-ol
Networked: 1
relevant articles (0 outcomes,
0 trials/studies)
Bio-Agent Context: Research Results
Experts
Related Diseases
1. | Dyskinesias (Dyskinesia)
01/01/2016
- " In contrast, oral treatment with 11-OH-NPa valerate (0.19 and 0.75 mg/kg) induced a dose-related reversal of motor disability and increased locomotor activity with only mild to moderate dyskinesia. " 01/01/2016
- " Oral administration of 11-OH-NPa valerate produced a rapid reversal of motor disability and, at effective dose levels, had a limited propensity to induce dyskinesia. " 01/01/2016
- " Locomotor activity, motor disability, and dyskinesia were assessed in MPTP-treated marmosets following the administration of apomorphine (0.075 mg/kg, subcutaneous and 0.28 to 1.12 mg/kg, oral) and 11-OH-NPa valerate (0.19, 0.38, and 0.75mg/kg, oral). "
|
|
Related Drugs and Biologics
Related Therapies and Procedures